AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER...

Related Keywords

Puerto Rico ,Japan ,United States ,Canada ,Michael Strapazon ,Jessica Akopyan ,Amgen Medinfo ,Kyowa Kirin Co Ltd ,Amgen ,Beigene Ltd ,Exchange Commission ,Therapeutics Inc ,European Union ,Teneobio Inc ,Studies Showed Sustained Reduction ,Combined Studies Evaluated Safety ,More Than ,Over Five Years After Completing ,Longest Studied ,Risk Open Label Extension ,Eastern Europe ,Cardiovascular Open Label Extension ,Dow Jones Industrial Average ,Best Workplaces ,Great Place ,Primary Hyperlipidemia ,Cardiovascular Outcomes Trial ,Pediatric Patients ,Prescribing Information ,Five Prime Therapeutics ,Thousand Oaks ,